Compare FNB & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FNB | LQDA |
|---|---|---|
| Founded | 1864 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8B | 5.5B |
| IPO Year | 2002 | 2020 |
| Metric | FNB | LQDA |
|---|---|---|
| Price | $17.73 | $67.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 11 |
| Target Price | $19.70 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 3.2M | 965.1K |
| Earning Date | 04-16-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.97% | N/A |
| EPS Growth | 22.83 | ★ 51.81 |
| EPS | 0.80 | ★ 1.26 |
| Revenue | N/A | ★ $158,320,000.00 |
| Revenue This Year | $14.12 | $278.87 |
| Revenue Next Year | $8.35 | $57.13 |
| P/E Ratio | ★ $22.39 | $52.72 |
| Revenue Growth | N/A | ★ 1031.18 |
| 52 Week Low | $14.46 | $21.15 |
| 52 Week High | $19.59 | $93.61 |
| Indicator | FNB | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 38.00 | 40.74 |
| Support Level | $17.87 | $62.86 |
| Resistance Level | $18.28 | $92.35 |
| Average True Range (ATR) | 0.30 | 2.48 |
| MACD | -0.03 | 0.32 |
| Stochastic Oscillator | 30.21 | 46.67 |
F N B Corp provides a full range of financial services, principally to consumers, corporations, governments, and small- to medium-sized businesses. It has three reportable business segments: Community Banking, Wealth Management, and Insurance. The majority of revenue is from the Community banking segment. It offers commercial & consumer banking services. Commercial banking solutions include corporate banking, small business banking, investment real estate financing, business credit, capital markets & lease financing. Consumer banking products & services include deposit products, mortgage lending, & consumer lending & a complete suite of mobile & online banking services.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.